To be clear: Ozempic is a diabetes drug while Wegovy is the weight loss counterpart. This “new" molecule does NOT address glucose management by improving sensitivity to insulin nor improving insulin response to the consumption of carbs. This new molecule will also NOT have a protective nor regenerative effect on pancreatic beta cell islets as GLP-1 does.
This, strictly, appears to target satiety for weight loss.
The only relation to semaglutide is that it's a peptide and it promotes weight loss. It has no other similarites with GLP-1. The comparison only exists to indicate efficacy of intended effect.
#Diabetes #Ozempic #GLP1
https://twit.social/@twitnews/114138689351869590
@bedast That's a shame, because last night and this morning was the first time in a month or so that I'd felt the really bad side effects, and boy oh boy would I like to not feel them again.
@sexybenfranklin There's some newer non-peptide GLP-1 RA drugs that are being developed that might be worth watching. They're oral rather than injected and may not have such severe side effects.
Though with the FDA being targeted for "efficiency" it's possible approval for these things may be delayed a while.